Firmer look to biotech fledglings gets
The Investment Column
Tuesday 31 October 1995
British Biotech is a case in point. Seen as one of the more serious players, with a market capitalisation now well over pounds 400m, it saw its share price plunge from 590p to 428p in February after it revealed problems with clinical trials of its then most promising drug, the anti-cancer compound batimastat. Since then the shares have soared close to 900p.
This roller-coaster ride is typical of the sector, but there are signs that it is moving onto a somewhat firmer footing, with institutions showing more serious interest in investing and the product portfolio edging towards commercial exploitation.
Last Friday's news that Chiroscience had become the first of the new biotech companies to win regulatory approval - for its painkiller dexketoprofen - was something of a milestone in this respect. The decision does not necessarily mean that other companies' products will be similarly blessed by the authorities, but it does show that the industry has the potential to move from the unquantifiable "blue sky" research stage to the creation of products that have the capacity to generate sales.
British Biotech's recovery from the February debacle is also testimony to its diversification strategy. Far from proving fatal, had it been the group's only product, batimastat's starring role has now been taken by a new oral anti-cancer drug, BB-2516. Indeed, the end of this month should see the release of data on trials of BB-2516, which could have a big effect on the share price.
Given the current level of the shares, British Bio's immediate financing needs should be assured by warrants exercisable at 525p over the turn of the year, which will raise pounds 47.5m.
Celltech, another of the better-regarded members of the sector, has also been steadily building a decent development portfolio, ranging from asthma to inflammatory bowel disorders. It has also been one of the most successful at cutting the risks associated with the sector by cultivating link-ups with big groups like Zeneca and Roche.
Even Scotia, the largest of the pack and a producer of evening primrose oil, has fought off its fringe image, with the market now getting excited about its anti-cancer compounds.
But investors should remember that profits from most of these companies are unlikely to emerge much before the next century. It would be strange if, before then, some of them did not fall by the wayside.
- 1 Autistic adults could take pure MDMA to 'reduce social anxiety'
- 2 Stolen Instagram photo sells for $90,000
- 3 Before you complain about your GP, this is what you need to know about actually doing the job
- 4 Charlie Charlie Challenge explained: not a Mexican demon being summoned — it's gravity
- 5 Paracetamol Challenge: Mother of girl killed by overdose pleads with teenagers not to take part
Iran launches anti-Isis cartoon competition 'to expose true nature of Islamic State'
'Don't blame all men for rape' campaign backfires spectacularly
Fifa corruption arrests: How Chuck Blazer rinsed money from the beautiful game
Fifa corruption live: Uefa to consider pulling teams from Fifa tournaments if Blatter stays
Ukip MP Douglas Carswell says he felt his safety was 'seriously at risk' after he was surrounded by anti-austerity protesters
EU referendum: David Cameron's rules are a 'democratic disgrace', says French-born Scottish politician set to be denied a vote
The day that Britain resigned as a global power
SNP fury as HS2 finds 'no business case' for taking fast train service to Scotland
Australian man punched in the face for defending Muslim women from abuse on train
A nation of inequality: How the UK is failing to feed its most vulnerable people
EU referendum: David Cameron to deny EU migrants and under-18s the chance to vote
iJobs Money & Business
£30 - 35k: Guru Careers: We are seeking a Pricing Analyst to join a leading e-...
£20000 - £25000 per annum + OTE £45K YR1: SThree: At SThree, we like to be dif...
£20000 - £25000 per annum + competitive: SThree: Did you know? SThree is a mul...
£55 - 65k (DOE): Guru Careers: A unique opportunity for a permanent C# Develop...